BRPI0514189A - composições farmacêuticas de estatina e métodos de tratamento relacionados - Google Patents
composições farmacêuticas de estatina e métodos de tratamento relacionadosInfo
- Publication number
- BRPI0514189A BRPI0514189A BRPI0514189-3A BRPI0514189A BRPI0514189A BR PI0514189 A BRPI0514189 A BR PI0514189A BR PI0514189 A BRPI0514189 A BR PI0514189A BR PI0514189 A BRPI0514189 A BR PI0514189A
- Authority
- BR
- Brazil
- Prior art keywords
- omega
- pharmaceutical compositions
- treatment methods
- solutions
- related treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
COMPOSIçõES FARMACêUTICAS DE ESTATINA E MéTODOS DE TRATAMENTO RELACIONADOS. A presente invenção refere-se a novas soluções de óleo ómega-3 de uma ou mais estatinas. Estas soluções são facilmente biodisponíveis. De forma notável, devido ao fato de as soluções da invenção conterem um óleo ómega-3 como o ingrediente principal, estas não só proporcionam um efeito anti-hipercolesterolêmico devido ao ingrediente ativo de estatina, estas também proporcionam dosagens diárias recomendadas de óleos ómega-3 (ou seja, aproximadamente 1 grama de óleo ómega-3 por dia), ou uma parte destas. A invenção também proporciona novos sais de uma ou mais estatinas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59954304P | 2004-08-06 | 2004-08-06 | |
US62351804P | 2004-10-29 | 2004-10-29 | |
US65598205P | 2005-02-24 | 2005-02-24 | |
PCT/US2005/027815 WO2006017698A2 (en) | 2004-08-06 | 2005-08-05 | Novel statin pharmaceutical compositions and related methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0514189A true BRPI0514189A (pt) | 2008-06-03 |
Family
ID=35839927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514189-3A BRPI0514189A (pt) | 2004-08-06 | 2005-08-05 | composições farmacêuticas de estatina e métodos de tratamento relacionados |
Country Status (11)
Country | Link |
---|---|
US (1) | US7642287B2 (pt) |
EP (1) | EP1786414A4 (pt) |
JP (1) | JP2008509154A (pt) |
KR (1) | KR20070038553A (pt) |
AU (1) | AU2005271413A1 (pt) |
BR (1) | BRPI0514189A (pt) |
CA (1) | CA2576196A1 (pt) |
IL (1) | IL180517A0 (pt) |
MX (1) | MX2007001553A (pt) |
NZ (1) | NZ552389A (pt) |
WO (1) | WO2006017698A2 (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2573316A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
EA014420B1 (ru) * | 2004-12-06 | 2010-12-30 | Релайэнт Фармасьютикалз, Инк. | Омега-3 жирные кислоты и дислипидемический агент для липидной терапии |
US20090239927A1 (en) * | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
US20060211763A1 (en) * | 2005-03-08 | 2006-09-21 | Abdel Fawzy | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
MX2008001597A (es) * | 2005-08-04 | 2008-04-04 | Transform Pharmaceuticals Inc | Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento. |
EP2081550B2 (en) | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
US20100119600A1 (en) * | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
US20080299187A1 (en) * | 2007-06-01 | 2008-12-04 | Joar Opheim | Substances for Reducing Occurence of Major Cardiac Events in Humans |
ITMI20072142A1 (it) * | 2007-11-08 | 2009-05-09 | Yervant Zarmanian | Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3 |
EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
GB0818472D0 (en) * | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
NZ594395A (en) | 2009-02-10 | 2014-01-31 | Amarin Pharmaceuticals Ie Ltd | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
EP2400840A4 (en) * | 2009-02-24 | 2012-08-01 | Madeira Therapeutics | LIQUID STATINE FORMULATIONS |
CN104146955A (zh) | 2009-03-09 | 2014-11-19 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
US20100239660A1 (en) * | 2009-03-19 | 2010-09-23 | Doughman Scott D | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions |
MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
SI3318255T1 (sl) | 2009-06-15 | 2021-07-30 | Amarin Pharmaceuticals Ireland Limited | Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom |
HUE029858T2 (en) * | 2009-07-24 | 2017-04-28 | Egyt Gyogyszervegyeszeti Gyar | Crystalline Form I of Rosuvastatin Zinc salt |
CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
WO2011047259A1 (en) * | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Compositions |
CA2803558C (en) | 2010-06-30 | 2018-05-29 | Mochida Pharmaceutical Co., Ltd. | .omega.3 fatty acid compound preparation |
WO2012032414A2 (en) * | 2010-09-08 | 2012-03-15 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture, a surfactant, and a statin |
KR20130139896A (ko) * | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US20150272920A1 (en) * | 2011-02-16 | 2015-10-01 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
SI2800563T1 (sl) | 2012-01-06 | 2018-11-30 | Omthera Pharmaceuticals Inc. | Z DPA obogateni sestavki omega-3 polinenasičenih maščobnih kislin v obliki proste kisline |
WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
WO2013142482A1 (en) | 2012-03-20 | 2013-09-26 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
CN104321053A (zh) | 2012-03-30 | 2015-01-28 | 桑茨利奥&孔帕尼股份有限公司 | ω-3脂肪酸酯组合物 |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
WO2013169648A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
BR112014029079B1 (pt) | 2012-05-22 | 2022-07-26 | Kuhnil Pharm. Co., Ltd | Composição farmacêutica para administração oral |
MX2020013922A (es) | 2012-06-29 | 2022-08-15 | Amarin Pharmaceuticals Ie Ltd | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
KR102108154B1 (ko) | 2017-02-08 | 2020-05-07 | (주)동구바이오제약 | 개선된 생체이용률을 갖는 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제 |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
WO2021074118A1 (en) * | 2019-10-15 | 2021-04-22 | Hermes Arzneimittel Gmbh | Liquid omega-3 fatty acid compositions for direct oral administration |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4231939A (en) * | 1979-11-26 | 1980-11-04 | Miles Laboratories, Inc. | 2,5-Dioxo-3H,6H-furo[(3,2-b]furan-3a,6a-diacetic acid and salts thereof |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5223415A (en) * | 1990-10-15 | 1993-06-29 | Merck & Co., Inc. | Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid) |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
DE69324504T2 (de) * | 1993-01-19 | 1999-08-26 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
AU743098B2 (en) * | 1997-12-10 | 2002-01-17 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US6365185B1 (en) * | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
SI20305A (sl) | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
SI20070A (sl) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
JP2002532539A (ja) | 1998-12-18 | 2002-10-02 | アボット・ラボラトリーズ | 脂質調節剤を含む新規な製剤 |
GB0000710D0 (en) | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
GR990100388A (el) | 1999-11-09 | 2001-07-31 | Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος.... | |
HUP0204005A3 (en) | 1999-12-14 | 2003-05-28 | Teva Gyogyszergyar Zartkoeruee | Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them |
DK2382970T3 (da) * | 2000-04-10 | 2013-03-25 | Teva Pharma | Stabile farmaceutiske sammensætninger, der indeholder 7-substitueret-3,5-dihydroxyheptansyrer eller 7-substitueret-3,5-dihydroxyheptensyrer |
DE60022987T2 (de) | 2000-05-22 | 2006-10-19 | Pro Aparts - Investimentos E Consultoria Lda., Funchal | Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält |
SI1292293T1 (en) * | 2000-06-09 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
AU2002211462A1 (en) | 2000-10-05 | 2002-04-22 | Teva Gyogyszergyar Reszvenytarsasag | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
JP3236282B1 (ja) * | 2000-10-16 | 2001-12-10 | 三共株式会社 | プラバスタチンを精製する方法 |
MXPA03004818A (es) | 2000-11-29 | 2003-09-10 | Smithkline Beecham Corp | Composicion conteniendo estatinas y calcio para salud cardiovascular mejorada. |
US6933291B2 (en) * | 2000-12-01 | 2005-08-23 | N.V. Nutricia | Cholesterol lowering supplement |
TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
ATE357216T1 (de) * | 2001-02-22 | 2007-04-15 | Jagotec Ag | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen |
EP1395254B1 (en) | 2001-06-12 | 2007-04-04 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
JP2005500307A (ja) | 2001-06-21 | 2005-01-06 | アンドルックス ファーマスーティカルズ インコーポレーテッド | プラバスタチンを含む安定な徐放性薬剤組成物 |
KR20040026705A (ko) * | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
CZ2004337A3 (cs) | 2001-08-16 | 2005-01-12 | Teva Pharmaceutical Industries Ltd. | Způsob přípravy vápenatých solí statinů |
KR100407758B1 (ko) * | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
KR100414334B1 (ko) * | 2001-09-29 | 2004-01-07 | 코바이오텍 (주) | 프라바스타틴 나트륨의 생산 방법 |
US6973191B2 (en) | 2001-11-02 | 2005-12-06 | Activcard | System and method for generating symmetric keys within a personal security device having minimal trust relationships |
US20040018248A1 (en) * | 2001-11-29 | 2004-01-29 | Adrianne Bendich | Composition containing statins and calcium for improved cardiovascular health |
AU2003245736A1 (en) * | 2002-02-14 | 2003-09-04 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
JP2005532362A (ja) * | 2002-06-13 | 2005-10-27 | ノバルティス アクチエンゲゼルシャフト | インドール誘導スタチンのカルシウム塩 |
US6844892B2 (en) * | 2002-06-13 | 2005-01-18 | Pentax Corporation | Multi-beam scanning device |
BR0312426A (pt) | 2002-07-03 | 2005-12-06 | Esperion Therapeutics Inc | Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit |
EP1651194B1 (en) | 2003-08-06 | 2010-03-31 | Galephar M/F | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
US20050032757A1 (en) * | 2003-08-06 | 2005-02-10 | Cho Suk H. | Nutritional supplements |
CA2657076A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
MXPA06003813A (es) | 2003-10-10 | 2006-06-14 | Lifecycle Pharma As | Forma solida de dosificacion que comprende un fibrato y una estatina. |
US20050096390A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
EP1680099B1 (en) * | 2003-11-07 | 2009-04-15 | JJ Pharma, Inc. | Hdl-boosting combination therapy complexes |
WO2005067921A1 (en) | 2004-01-20 | 2005-07-28 | Panacea Biotec Ltd., | Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
BRPI0509422A (pt) | 2004-04-28 | 2007-09-04 | Unilever Nv | óleo comestìvel, processo para a preparação de um óleo comestìvel e uso de um óleo comestìvel |
US20050267197A1 (en) * | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses |
WO2006002127A1 (en) | 2004-06-21 | 2006-01-05 | Fairfield Clinical Trials, Llc | Transdermal delivery system for statin combination therapy |
ITRM20040395A1 (it) | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
US20070259022A1 (en) | 2004-08-23 | 2007-11-08 | Molhuizen Henricus O F | Composition Comprising Statin |
-
2005
- 2005-08-05 EP EP05778295A patent/EP1786414A4/en not_active Withdrawn
- 2005-08-05 WO PCT/US2005/027815 patent/WO2006017698A2/en active Application Filing
- 2005-08-05 JP JP2007525011A patent/JP2008509154A/ja active Pending
- 2005-08-05 AU AU2005271413A patent/AU2005271413A1/en not_active Abandoned
- 2005-08-05 US US11/197,880 patent/US7642287B2/en not_active Expired - Fee Related
- 2005-08-05 MX MX2007001553A patent/MX2007001553A/es active IP Right Grant
- 2005-08-05 CA CA002576196A patent/CA2576196A1/en not_active Abandoned
- 2005-08-05 BR BRPI0514189-3A patent/BRPI0514189A/pt not_active IP Right Cessation
- 2005-08-05 NZ NZ552389A patent/NZ552389A/xx not_active IP Right Cessation
- 2005-08-05 KR KR1020077003811A patent/KR20070038553A/ko not_active Application Discontinuation
-
2007
- 2007-01-02 IL IL180517A patent/IL180517A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US7642287B2 (en) | 2010-01-05 |
KR20070038553A (ko) | 2007-04-10 |
JP2008509154A (ja) | 2008-03-27 |
EP1786414A2 (en) | 2007-05-23 |
CA2576196A1 (en) | 2006-02-16 |
EP1786414A4 (en) | 2008-04-09 |
WO2006017698A3 (en) | 2006-07-06 |
IL180517A0 (en) | 2008-03-20 |
AU2005271413A1 (en) | 2006-02-16 |
NZ552389A (en) | 2009-05-31 |
MX2007001553A (es) | 2008-03-07 |
US20060034815A1 (en) | 2006-02-16 |
WO2006017698A2 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514189A (pt) | composições farmacêuticas de estatina e métodos de tratamento relacionados | |
BRPI0513082A (pt) | formulações de fenofibrato e métodos de tratamento relacionados | |
EA200970081A1 (ru) | Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения | |
BR0210139A (pt) | Composições farmacêuticas | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
SG145693A1 (en) | Amino acid prodrugs | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
BRPI0519265A2 (pt) | composiÇÕes incluindo ferro | |
MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
EA200900023A1 (ru) | Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли | |
BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
BR0308613A (pt) | Combinação de compostos orgânicos | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
BRPI0620229B8 (pt) | formulações farmaceuticas e processos de produção da ditas formulações | |
BRPI0517846A (pt) | azaindolcarboxamidas | |
EA200600280A1 (ru) | Композиции на основе производных липопептидных антибиотиков и способы их применения | |
EA200800698A1 (ru) | Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы | |
BR0300709A (pt) | Sal de perindopril e as composições farmacêuticas contendo o mesmo | |
HUP0301819A2 (hu) | Illóolajok alkalmazása Helicobacter-szerű organizmusok által előidézett gyomor- és bélrendszeri fertőzések leküzdésére | |
DE60335991D1 (de) | Filmueberzug fuer tabletten und kapletten | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
FR2887150B1 (fr) | Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |